Genetic Signatures Ltd. (GSS) AI Stock Analysis

• Market Cap: AU$60.19M
• Dividend Yield: N/A
• Average Volume (3M): 149.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: 62.81%
• EPS Growth: 16.37%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.02
• Shares Outstanding: 227,138,820
• 10 Day Avg. Volume: 161,537
• 30 Day Avg. Volume: 149,454
• PEG Ratio: 0.21
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 5.20
• P/FCF Ratio: -6.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.55
• Price Target Upside: 111.54% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: AU$0.50 ▲(92.31% Upside)

Genetic Signatures Ltd. is facing significant financial and valuation challenges. The company's negative profitability and cash flow issues are major concerns, compounded by a bearish technical outlook. The lack of earnings call data and corporate events further limits positive catalysts for the stock.

Positive Factors

Revenue Growth

The company has shown a positive trend in revenue growth, indicating potential market expansion and increased demand for its products.

Market Position

GSS's focus on innovative molecular diagnostics positions it well in the growing healthcare market, enhancing its competitive edge.

Strong Equity Base

A strong equity base with minimal leverage provides financial stability and flexibility for future growth initiatives.

Negative Factors

Profitability Challenges

Persistent profitability challenges hinder the company's ability to generate sustainable earnings, impacting long-term viability.

Cash Flow Issues

Ongoing cash flow issues limit the company's capacity to reinvest in growth and manage operational expenses effectively.

Negative Return on Equity

Negative return on equity indicates inefficiency in using shareholders' funds to generate profits, affecting investor confidence.

Genetic Signatures Ltd. Business Overview & Revenue Model

Company Description

Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. The company was incorporated in 2001 and is headquartered in Newtown, Australia.

How the Company Makes Money

Genetic Signatures Ltd. generates revenue through the sale of its diagnostic tests and related products to laboratories and healthcare providers. The company employs a direct sales model as well as partnerships with distributors to reach a wider market. Key revenue streams come from the sales of its assays, which are used for pathogen detection in clinical diagnostics. Additionally, GSS may earn revenue through licensing agreements or collaborations with other companies in the healthcare and biotechnology sectors, enhancing its market presence and product offerings. The company’s growth is also supported by ongoing developments in molecular diagnostics and increased demand for rapid testing solutions.

Genetic Signatures Ltd. Financial Statement Overview

Summary

Genetic Signatures Ltd. faces significant financial challenges, particularly in profitability and cash flow generation. Despite a strong equity base and low leverage, the company's inability to generate positive earnings and cash flow poses risks to its financial stability. Recent revenue growth is a positive sign, but sustained improvement in profitability and cash flow is crucial for long-term success.

Income Statement

Genetic Signatures Ltd. has experienced fluctuating revenue growth, with a recent positive trend of 8.45% in the latest year. However, profitability remains a significant concern, as indicated by negative net profit margins and EBIT margins over the past years. The company has struggled to maintain positive gross profit margins, and the consistent negative EBIT and EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The company's balance sheet shows a strong equity position with a low debt-to-equity ratio of 0.0158, indicating minimal leverage. However, the return on equity is negative, reflecting the company's inability to generate profits from its equity base. The equity ratio remains stable, suggesting a solid capital structure despite profitability issues.

Cash Flow

Cash flow analysis reveals a challenging situation, with negative operating and free cash flows. Although there is a slight improvement in free cash flow growth, the operating cash flow to net income ratio is negative, indicating cash flow issues. The free cash flow to net income ratio is above 1, suggesting that free cash flow is relatively better than net income, but overall cash generation remains weak.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	15.90M	15.90M	9.77M	16.94M	35.42M	28.28M
Gross Profit	-2.39M	7.78M	4.31M	-12.74M	7.21M	4.27M
EBITDA	-15.87M	-16.08M	-19.82M	-13.14M	4.70M	3.22M
Net Income	-20.10M	-20.10M	-17.86M	-14.05M	3.06M	1.76M
Balance Sheet
Total Assets	54.63M	54.63M	67.29M	49.08M	59.65M	54.05M
Cash, Cash Equivalents and Short-Term Investments	31.30M	31.30M	36.25M	16.35M	36.90M	30.12M
Total Debt	791.00K	791.00K	1.22M	0.00	34.00K	399.00K
Total Liabilities	4.54M	4.54M	6.18M	6.16M	4.85M	4.71M
Stockholders Equity	50.09M	50.09M	61.10M	42.91M	54.80M	49.34M
Cash Flow
Free Cash Flow	-12.94M	-13.19M	-14.91M	-20.55M	6.82M	-784.00K
Operating Cash Flow	-12.29M	-12.29M	-10.12M	-12.45M	9.81M	4.20M
Investing Cash Flow	-24.30M	-24.30M	-4.79M	-8.09M	-2.99M	-4.98M
Financing Cash Flow	7.79M	7.79M	34.81M	-23.00K	-101.00K	-190.00K

Genetic Signatures Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GSS, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.29, and below the 200-day MA of 0.38, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.74 is Neutral, neither overbought nor oversold. The STOCH value of 37.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:GSS.

Genetic Signatures Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTE	64 Neutral	AU$58.08M	30.83	98.18%	―	11.93%	2.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LDX	50 Neutral	AU$169.25M	―	-111.23%	―	12.96%	40.81%
BDX	48 Neutral	AU$34.21M	-4.70	-97.79%	―	―	23.85%
RHY	44 Neutral	AU$27.68M	-6.59	-501.54%	―	―	56.42%
GSS	41 Neutral	AU$60.19M	-2.93	-36.16%	―	62.81%	16.37%
IIQ	38 Underperform	AU$49.96M	-5.78	-37.78%	―	2.33%	12.50%

Genetic Signatures Ltd. Corporate Events

Genetic Signatures Announces Director’s Acquisition of Restricted Rights

Genetic Signatures Limited announced a change in the director’s interest, with Anne Lockwood acquiring 250,000 Restricted Rights as approved at the company’s Annual General Meeting. This change reflects the company’s ongoing commitment to align its leadership’s interests with its strategic goals, potentially impacting its governance and stakeholder relations positively.

Genetic Signatures Ltd. Announces Cessation of Securities

Genetic Signatures Ltd. announced the cessation of 150,000 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure, potentially affecting investor perceptions and market positioning.

Genetic Signatures Ltd Announces 2025 AGM Results

Genetic Signatures Ltd held its 2025 Annual General Meeting, where resolutions were put to shareholders, resulting in the re-election of directors and approval of remuneration-related resolutions. These outcomes indicate continued support for the company’s leadership and strategic direction, potentially impacting its market positioning and stakeholder confidence positively.

Genetic Signatures Announces CFO Resignation

Genetic Signatures Ltd announced the resignation of its Chief Financial and Operating Officer, Karl Pechmann, effective January 30, 2026. Pechmann has been instrumental in enhancing the company’s financial management and operational performance since joining in June 2023. The company has initiated a search for his successor to ensure continued operational stability. CEO Allison Rossiter praised Pechmann’s contributions, noting his leadership during challenging times and his role in positioning the company for future growth.

Genetic Signatures Ltd. Issues Performance Rights to Boost Employee Engagement

Genetic Signatures Ltd. announced the issuance of 1,016,859 performance rights as part of an employee incentive scheme. This move is expected to align employee interests with company goals, potentially enhancing productivity and commitment, and may positively impact the company’s market position and stakeholder value.

Genetic Signatures Updates CEO Remuneration Package

Genetic Signatures Ltd has updated the remuneration for its CEO, Allison Rossiter, with a new base salary of A$515,000 per annum and a long-term incentive plan involving performance rights. These changes, effective from October 2025, are part of a board review and aim to align the CEO’s compensation with long-term service and performance goals.

Genetic Signatures Ltd Reports Record Quarterly Revenue and Strategic US Expansion

Genetic Signatures Ltd reported a strong start to FY2026 with a 20% increase in quarterly sales to $5.4 million, marking its highest revenue since COVID. The company achieved commercial success across all operating regions, notably signing two significant contracts in the US, which is a key market for expansion. The company’s strategic focus on targeted US states is expected to drive further growth and customer engagement. Additionally, the appointment of a new CTO and a robust cash position of $28.2 million underscore the company’s strengthened operational capabilities and market positioning.

Genetic Signatures Ltd Announces 2025 Annual General Meeting Details

Genetic Signatures Ltd has announced the details of its 2025 Annual General Meeting, scheduled for November 17, 2025. The meeting will cover the consideration of financial reports, allow shareholder engagement with the company’s management and auditors, and include resolutions for the re-election of directors. This AGM is an opportunity for stakeholders to engage with the company’s strategic direction and governance.